Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

The in vitro activity of monoclonal antibodies and antiviral agents was assessed against the sublineages of the SARS-CoV-2 variant of concern omicron (BA.1, BA.1.1, and BA.2). Variable activity of the monoclonal antibodies was observed.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 386; no. 15; pp. 1475 - 1477
Main Authors Takashita, Emi, Kinoshita, Noriko, Yamayoshi, Seiya, Sakai-Tagawa, Yuko, Fujisaki, Seiichiro, Ito, Mutsumi, Iwatsuki-Horimoto, Kiyoko, Halfmann, Peter, Watanabe, Shinji, Maeda, Kenji, Imai, Masaki, Mitsuya, Hiroaki, Ohmagari, Norio, Takeda, Makoto, Hasegawa, Hideki, Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 14.04.2022
Subjects
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Coronavirus
Coronaviruses
Correspondence
COVID-19
COVID-19 - drug therapy
Disease transmission
Global Health
Humans
Infectious Disease
Infectious Disease General
Infectious diseases
Influenza
Monoclonal antibodies
Pathogenesis
Proteins
R&D
Research & development
RNA polymerase
SARS-CoV-2 - drug effects
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus
Viral Infections
Japan
India
Online AccessGet full text

Cover

More Information
Summary:The in vitro activity of monoclonal antibodies and antiviral agents was assessed against the sublineages of the SARS-CoV-2 variant of concern omicron (BA.1, BA.1.1, and BA.2). Variable activity of the monoclonal antibodies was observed.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
Drs. Takashita, Kinoshita, and Yamayoshi contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2201933